Company* (Country; Symbol) |
Company |
Type/Product Area |
Terms/Details (Date) |
| |||
Codexis Inc.* |
Shell Oil Products US |
Collaboration to explore enhanced methods of converting biomass to biofuels |
Codexis will use its biocatalytic approach in the effort; terms of the deal were not disclosed (11/16) |
| |||
Dyadic International Inc. (AMEX:DIL) |
Abengoa Bioenergy R&D Inc. |
Deal to develop a cost-effective enzyme production system in Abengoa's bioethanol production process |
Abengoa is purchasing 2.136M shares of Dyadic for $10M; Dyadic also may be entititled to license fees, technology transfer fees and royalties under the three-year deal (10/27) |
| |||
Ortec International Inc. (OTC BB:OTCI) |
Paul Capital Healthcare |
They amended 2001 deal covering future Orcel-related revenue |
Paul Capital is exchanging its interest in OrCel-related revenue for $10M in Ortec convertible preferred stock (11/29) |
| |||
Perfusion Therapeutics Inc.* (Canada) |
Covalon Technologies Ltd. (Canada) |
Covalon completed its acquisition of Perfusion's endothelial PAS domain protein 1-based gene therapy technology |
Perfusion is entitled to receive up to 1.1M Covalon shares based on various milestones; the cell engineering platform is being developed for improving blood vessel development (10/24) |
| |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. |